Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[The prognostic significance of proportion of blasts in bone marrow on day 14 during induction chemotherapy in patients with adult Ph-negative acute lymphoblastic leukemia].
Jia JS, Yang SM, Wang J, Jiang H, Zhao T, Bao L, Shi HX, Lu J, Zhu HH, Lai YY, Jiang B, Huang XJ, Jiang Q. Jia JS, et al. Among authors: shi hx. Zhonghua Xue Ye Xue Za Zhi. 2016 Jun 14;37(6):497-502. doi: 10.3760/cma.j.issn.0253-2727.2016.06.011. Zhonghua Xue Ye Xue Za Zhi. 2016. PMID: 27431075 Free PMC article. Chinese.
[Clinical, molecular and cytogenetic characteristics of newly diagnosed adult acute myeloid patients with TP53 gene mutation].
Chen WM, Liu H, Li LD, Long LY, Lai YY, Shi HX, Zhao XS, Jiang H, Jiang Q, Liu YR, Qin YZ. Chen WM, et al. Among authors: shi hx. Zhonghua Xue Ye Xue Za Zhi. 2019 Jun 14;40(6):528-531. doi: 10.3760/cma.j.issn.0253-2727.2019.06.016. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 31340630 Free PMC article. Chinese. No abstract available.
[Observation on the efficacy of consolidation chemotherapy combined with allogeneic natural killer cell infusion in the treatment of low and moderate risk acute myeloid leukemia].
Wang CJ, Huang XJ, Gong LZ, Jia JS, Liu XH, Wang Y, Yan CH, Chang YJ, Zhao XS, Shi HX, Lai YY, Jiang H. Wang CJ, et al. Among authors: shi hx. Zhonghua Xue Ye Xue Za Zhi. 2019 Oct 14;40(10):812-817. doi: 10.3760/cma.j.issn.0253-2727.2019.10.003. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 31775478 Free PMC article. Chinese.
[Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics].
Dou XL, Yu L, Qin YZ, Shi HX, Lai YY, Hou Y, Huang XJ, Jiang Q. Dou XL, et al. Among authors: shi hx. Zhonghua Xue Ye Xue Za Zhi. 2019 Nov 14;40(11):924-931. doi: 10.3760/cma.j.issn.0253-2727.2019.11.008. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 31856442 Free PMC article. Chinese.
[Fertility and disease outcomes in patients with chronic myeloid leukemia].
Dou XL, Qin YZ, Shi HX, Lai YY, Hou Y, Huang XJ, Jiang Q. Dou XL, et al. Among authors: shi hx. Zhonghua Xue Ye Xue Za Zhi. 2019 Dec 14;40(12):980-985. doi: 10.3760/cma.j.issn.0253-2727.2019.12.002. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 32023726 Free PMC article. Chinese.
[Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase].
Yuan T, Lai YY, Qin YZ, Shi HX, Huang XJ, Hou Y, Jiang Q. Yuan T, et al. Among authors: shi hx. Zhonghua Xue Ye Xue Za Zhi. 2020 Feb 14;41(2):93-99. doi: 10.3760/cma.j.issn.0253-2727.2020.02.002. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 32135623 Free PMC article. Chinese.
163 results